Otsuka’s Astex secures $515m Roche deal for cell-cycle breast cancer candidates
Discover why Roche and Otsuka-owned Astex are pursuing a $515 million cell-cycle breast cancer programme and what risks remain.
Pharma & Biotech
Pharma & Biotech
Can Lineage turn early retinal repair signals into a credible late-stage OpRegen pathway?
Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.
Pharma & Biotech
AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.
Pharma & Biotech
Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment
Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.
Medical Devices & Diagnostics
What Roche’s $1.05bn PathAI move reveals about the future of pathology labs
Roche wants AI pathology at scale. PathAI gives it the tissue-analysis layer needed to tighten diagnostics, trials, and precision oncology.
Pharma & Biotech
Can Genentech’s Enspryng become the first approved treatment for MOGAD after the Phase III METEOROID win?
Genentech’s Enspryng cut MOGAD relapse risk by 68% in Phase III. Read what the data could mean for regulators, clinicians, and the rare disease market.
Pharma & Biotech
How Alnylam Pharmaceuticals is using new ACC.26 data to deepen the case for vutrisiran and zilebesiran
See why Alnylam Pharmaceuticals’ new ACC.26 data on vutrisiran and zilebesiran could reshape cardiovascular strategy and market expectations.
Pharma & Biotech
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
Pharma & Biotech
Gazyva’s ALLEGORY data: what the SRI-4 and DORIS remission outcomes mean for lupus care
Genentech's obinutuzumab met all ALLEGORY phase III endpoints in SLE. What the remission and flare data mean for lupus treatment strategy.
Pharma & Biotech
Can Genentech’s CT-388 challenge obesity drug giants with 22.5% weight loss and β-arrestin bias?
Genentech’s CT-388 hit 22.5% weight loss in Phase II. Find out what this means for obesity drugs, clinical durability, and market strategy in 2026.